Kato S, Luyckx V A, Ots M, Lee K W, Ziai F, Troy J L, Brenner B M, MacKenzie H S
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Kidney Int. 1999 Sep;56(3):1037-48. doi: 10.1046/j.1523-1755.1999.00643.x.
Glomerular macrophage accumulation in diabetes implicates monocyte recruitment mechanisms in the pathogenesis of diabetic nephropathy. To test the hypothesis that overexpression of monocyte chemoattractant protein-1 (MCP-1), a monocyte chemoattractant, is attenuated by renin-angiotensin system (RAS) inhibition, we assessed expression of genes regulating monocyte transmigration in the glomeruli of diabetic rats.
Competitive reverse transcription-polymerase chain reaction (RT-PCR) was used to semiquantitate mRNA expression in glomeruli harvested by sieving at serial intervals after the induction of diabetes by streptozotocin in Munich-Wistar rats. Although subject to limitations, competitive RT-PCR provides an objective measure suited to the minute quantities of RNA extractable from glomerular isolates.
Time-dependent elevation of MCP-1 expression was dramatically suppressed by treatment with the angiotensin-converting enzyme inhibitor enalapril or the AT1 receptor antagonist candesartan, and was closely associated with effects on proteinuria and glomerular macrophage number. By contrast, no sustained suppression of the cell adhesion molecules intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 or the classic MCP-1 stimulators tumor necrosis factor-alpha or interleukin-1beta followed RAS inhibition, and suppression of transforming growth factor-beta1 expression was transient.
These data suggest that glomerular macrophage recruitment in experimental diabetes is largely determined by angiotensin-stimulated MCP-1 expression. We conclude that the RAS is an important regulator of local MCP-1 expression, either directly or through glomerular hemodynamic effects, and that our data strongly implicate macrophage recruitment and activation in the pathogenesis of early diabetic glomerular injury.
糖尿病时肾小球巨噬细胞积聚提示单核细胞募集机制参与了糖尿病肾病的发病过程。为了验证单核细胞趋化蛋白-1(MCP-1,一种单核细胞趋化因子)的过表达可被肾素-血管紧张素系统(RAS)抑制所减弱这一假说,我们评估了糖尿病大鼠肾小球中调节单核细胞迁移的基因表达。
采用竞争性逆转录-聚合酶链反应(RT-PCR)对慕尼黑-维斯特大鼠经链脲佐菌素诱导糖尿病后,在不同时间间隔通过筛网收集的肾小球中的mRNA表达进行半定量分析。尽管存在局限性,但竞争性RT-PCR提供了一种适用于从肾小球分离物中提取的微量RNA的客观测量方法。
用血管紧张素转换酶抑制剂依那普利或AT1受体拮抗剂坎地沙坦治疗可显著抑制MCP-1表达的时间依赖性升高,且与对蛋白尿和肾小球巨噬细胞数量的影响密切相关。相比之下,RAS抑制后,细胞间黏附分子-1或血管细胞黏附分子-1等细胞黏附分子以及经典的MCP-1刺激因子肿瘤坏死因子-α或白细胞介素-1β并未受到持续抑制,转化生长因子-β1表达的抑制也是短暂的。
这些数据表明,实验性糖尿病中肾小球巨噬细胞的募集很大程度上由血管紧张素刺激的MCP-1表达所决定。我们得出结论,RAS是局部MCP-1表达的重要调节因子,可直接或通过肾小球血流动力学效应发挥作用,且我们的数据有力地表明巨噬细胞的募集和激活参与了早期糖尿病肾小球损伤的发病过程。